Oncopeptides AB (FRA:OND) Float Percentage Of Total Shares Outstanding: 0.00% (As of Jul. 01, 2026)


FRA:OND Oncopeptides AB FRA:OND
28 GF Score
Price €0.15
GF Value €0.37
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Oncopeptides AB Float Percentage Of Total Shares Outstanding?

Oncopeptides AB FRA:OND +5.66% 28 Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 01, 2026. GuruFocus rates FRA:OND with a GF Score™ of 28/100 and a GF Value™ of €0.37 (Possible Value Trap). The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Oncopeptides AB's float shares is 0.00 Mil. Oncopeptides AB's total shares outstanding is 381.15 Mil. Oncopeptides AB's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Oncopeptides AB's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Oncopeptides AB's Institutional Ownership is 4.06%.

FRA:OND
28GF Score
Oncopeptides AB FRA:OND
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncopeptides AB Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Oncopeptides AB's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/381.15
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 0.00% mean?
Oncopeptides AB (FRA:OND) has a Float Percentage Of Total Shares Outstanding of 0.00% as of Jul. 01, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Oncopeptides AB and its competitors.
Is Oncopeptides AB's Float Percentage Of Total Shares Outstanding too high?
Oncopeptides AB's current Float Percentage Of Total Shares Outstanding is 0.00%. Overall, Oncopeptides AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
Oncopeptides AB's Float Percentage Of Total Shares Outstanding of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current Float Percentage Of Total Shares Outstanding is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.37, compared to a current price of €0.15 — trading 60.6% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 0.00%. Oncopeptides AB's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncopeptides AB (FRA:OND) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of €0.15 is trading 60.6% below its estimated GF Value™ of €0.37. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for FRA:OND:

  • Float Percentage Of Total Shares Outstanding: 0.00%
  • GF Value™: €0.37 vs. price of €0.15 (60.6% below fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncopeptides AB Business Description

Other Exchanges ONCO:SwedenONCOs:UK0RN4:UK
Address Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
28GF Score

Get the complete analysis for FRA:OND

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.37
GF Value